Your present location:HOMENewsCompany news > Qilu Pharma launched another blockbuster generic product, Bortezomib in China
News Detail

Qilu Pharma launched another blockbuster generic product, Bortezomib in China

Writer:QILU PHARMACEUTICALSource:QILU PHARMACEUTICAL Number of visits: Date:6/2/2018 04:57 PM
After 6 years’ hard work on the Bortezomib project, Qilu proudly launched another blockbuster generic product, Bortezomib for Injection to the Chinese market, offering another treatment solution for multiple myeloma patients in China. It will bring down the price greatly and patients will also benefit from the wide availability of this affordable generic drug with 1/3 lower finance burden. In addition, Qilu filed the application for Bortezomib for Injection to USFDA and EMA in 2017 and will be approved in next two years.